Urovant Sciences licenses vibegron from Merck Inc. and will initiate a Phase III trial in 2017 for overactive bladder treatment.
Roivant Sciences, announced the formation of Urovant Sciences, a new company focused on developing innovative therapies for urologic conditions. Urovant's lead therapeutic candidate is vibegron, an oral ?3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron (formerly MK-4618) from Merck Sharp & Dohme Corp., a subsidiary of Merck Inc.,
Urovant plans to initiate a multinational Phase III registration program for vibegron in 2017.
Japanese rights to the drug are licensed from Merck Inc. by Kyorin Pharmaceutical Co. Ltd which will co develop and co market the drug with Kissei Pharmaceutical Co. Ltd.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.